Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation.

[1]  G. Lip,et al.  International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives , 2016, Journal of the American Heart Association.

[2]  A. Camm,et al.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation , 2016, Heart.

[3]  Joshua D. Brown,et al.  A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras , 2016, Drugs & Aging.

[4]  M. Turakhia,et al.  Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. , 2016, JAMA cardiology.

[5]  Z. Goldberger,et al.  National Trends in Ambulatory Oral Anticoagulant Use. , 2015, The American journal of medicine.

[6]  Eric E. Smith,et al.  Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack , 2015, Circulation. Cardiovascular quality and outcomes.

[7]  M. Brookhart,et al.  Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. , 2015, The American journal of cardiology.

[8]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[9]  T. Brennan,et al.  Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. , 2014, The American journal of medicine.

[10]  Deepak L. Bhatt,et al.  Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). , 2014, Journal of the American College of Cardiology.

[11]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[12]  B. Martin,et al.  The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective , 2013, Journal of managed care pharmacy : JMCP.

[13]  D. Singer,et al.  Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation , 2013, Journal of the American Heart Association.

[14]  D. Singer,et al.  Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2013, Circulation.

[15]  B. Gersh,et al.  Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry , 2013, Journal of the American Heart Association.

[16]  R. Stafford,et al.  National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011 , 2012, Circulation. Cardiovascular quality and outcomes.

[17]  J. Spertus,et al.  Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians , 2012, Journal of multidisciplinary healthcare.

[18]  A. Banerjee,et al.  Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project , 2012, European Journal of Heart Failure.

[19]  L. Fauchier,et al.  Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. , 2011, Chest.

[20]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[21]  Donna Buchanan,et al.  Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. , 2010, Journal of the American College of Cardiology.

[22]  P. Zimetbaum,et al.  Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? , 2010, The American journal of medicine.

[23]  J. Plumb,et al.  Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? , 2008, Journal of thrombosis and haemostasis : JTH.

[24]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[25]  S. Lévy,et al.  Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. , 2007, American heart journal.

[26]  M. Josephson,et al.  Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. , 2006, The American journal of cardiology.

[27]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[28]  Carl van Walraven,et al.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. , 2002, JAMA.

[29]  D. Singer,et al.  Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.